<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT04501120</url>
  </required_header>
  <id_info>
    <org_study_id>APG2575AC101</org_study_id>
    <nct_id>NCT04501120</nct_id>
  </id_info>
  <brief_title>Study of APG2575 Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML</brief_title>
  <official_title>A Phase Ib Study of the Safety, Pharmacokinetic of APG-2575 Single Agent and in Combination With Homoharringtonine or Azacitidine in Patients With Relapsed/Refractory AML</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ascentage Pharma Group Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Suzhou Yasheng Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ascentage Pharma Group Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, pharmacokinetic profile of APG-2575 single&#xD;
      agent and in combination with HHT/AZA in patients with relapsed/refractory AML and related&#xD;
      myeloid malignancies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, multi-center Phase Ib study of safety, PK of APG-2575 as single agent&#xD;
      or in combination with HHT or AZA in relapsed/refractory AML and related myeloid malignancies&#xD;
      patients.&#xD;
&#xD;
      This study consists of three stages: The first stage is the APG-2575 single agent&#xD;
      dose-escalation study. The second stage is the APG-2575 combined with HHT/AZA dose-escalation&#xD;
      study. The third stage is the MTD/RP2D expansion cohort study of the combination regimen.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 28, 2020</start_date>
  <completion_date type="Anticipated">August 2025</completion_date>
  <primary_completion_date type="Anticipated">August 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Limiting Toxicities (DLT)</measure>
    <time_frame>28 days</time_frame>
    <description>DLT will be graded according to NCI CTCAE Version 5.0. DLT will be defined as clinically significant drug-related adverse events during cycle one.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose(RP2D)</measure>
    <time_frame>28 days</time_frame>
    <description>MTD/RP2D will be determined based on DLTs observed during cycle one.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax)</measure>
    <time_frame>28 days</time_frame>
    <description>Cmax of APG-2575 will be assessed in the patients in single agent or combo study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC)</measure>
    <time_frame>28 days</time_frame>
    <description>AUC of APG-2575 will be assessed in the patients in single agent or combo study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>Up to 6 cycles (each cycle is 28 days).</time_frame>
    <description>ORR is defined by CR+ CRi + PR(according to IWG AML(2003)).Response will be evaluated on cycle 1 and every even cycles till completing 6 cycles treatment or end of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression free survival (PFS)</measure>
    <time_frame>Up to 2 years.</time_frame>
    <description>From date of treatment start until the date of progression or the date of death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of response (DOR)</measure>
    <time_frame>Up to 2 years.</time_frame>
    <description>From date of response until the date of progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival (OS)</measure>
    <time_frame>Up to 2 years.</time_frame>
    <description>From date of treatment start until the date of death due to any cause.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">284</enrollment>
  <condition>Relapsed/Refractory Acute Myeloid Leukaemia</condition>
  <condition>Myeloid Malignancy</condition>
  <arm_group>
    <arm_group_label>APG2575 single agent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>APG-2575 orally once daily starting from 200mg and will be increased in subsequent cohorts to 400mg, 600mg, 800mg, to determine the MTD/RP2D.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>APG2575+reduced-dose HHT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>APG-2575 MTD/RP2D-1 and MTD/RP2D combines with reduced-dose HHT in R/R AML, MPAL, BPDCN, CMML.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>APG2575+ standard-dose HHT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>APG-2575 MTD/RP2D-1 and MTD/RP2D combines with standard-dose HHT in R/R AML, MPAL, BPDCN, CMML.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>APG2575+ AZA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>APG-2575 MTD/RP2D-1 and MTD/RP2D combines with AZA in R/R AML, MPAL, BPDCN, CMML.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>APG2575+ AZA(HR-MDS.)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>APG-2575 MTD/RP2D-1 and MTD/RP2D combines with AZA in HR-MDS.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>APG2575+ AZA(Naïve AML.)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>APG-2575 MTD/RP2D-1 and MTD/RP2D combines with AZA in treatment naïve AML.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APG-2575</intervention_name>
    <description>APG-2575 orally once daily, every 28 days as a cycle.</description>
    <arm_group_label>APG2575 single agent</arm_group_label>
    <arm_group_label>APG2575+ AZA</arm_group_label>
    <arm_group_label>APG2575+ AZA(Naïve AML.)</arm_group_label>
    <arm_group_label>APG2575+ standard-dose HHT</arm_group_label>
    <arm_group_label>APG2575+reduced-dose HHT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reduced-dose HHT</intervention_name>
    <description>1mg IV QD on Days 1-14 (28-day cycle).</description>
    <arm_group_label>APG2575+reduced-dose HHT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>standard-dose HHT</intervention_name>
    <description>2mg/m^2 IV QD on Days 1-7 (28-day cycle).</description>
    <arm_group_label>APG2575+ standard-dose HHT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacitidine</intervention_name>
    <description>75 mg/m^2 SC or Iv gtt QD on Days 1- 7 (28-day cycle).</description>
    <arm_group_label>APG2575+ AZA</arm_group_label>
    <arm_group_label>APG2575+ AZA(HR-MDS.)</arm_group_label>
    <arm_group_label>APG2575+ AZA(Naïve AML.)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APG-2575</intervention_name>
    <description>APG-2575 orally once daily for 14 days, every 28 days as a cycle.</description>
    <arm_group_label>APG2575+ AZA(HR-MDS.)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects who meet each of the following inclusion criteria are eligible to participate in&#xD;
        this study:&#xD;
&#xD;
          1. In accordance with the World Health Organization (WHO) 2016 diagnostic criteria for&#xD;
             relapsed or refractory acute myeloid leukemia (AML), Mixed phenotype acute&#xD;
             leukemia(MPAL), Chronic myelomonocytic leukemia (CMML), Higher-risk myelodysplastic&#xD;
             syndrome (HR-MDS) , Blastic plasmacytoid dendritic cell neoplasm (BPDCN) and naïve AML&#xD;
             ineligible for treatment with a standard chemotherapy due to age or comorbidities.&#xD;
&#xD;
          2. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS): 0 -2 (0 to 3 for&#xD;
             participants &gt;= 60 to 74 years of age who are evaluated as ineligible for treatment&#xD;
             with standard chemotherapy).&#xD;
&#xD;
          3. Subjects can accept oral administration of APG-2575.&#xD;
&#xD;
          4. Life expectancy ≥ 3 months.&#xD;
&#xD;
          5. Adequate renal and liver function.&#xD;
&#xD;
          6. Males, female patients of childbearing potential (postmenopausal women who must have&#xD;
             been menopausal for at least 12 months to be considered infertile) and their partners&#xD;
             voluntarily take contraception which the investigator considers effective during&#xD;
             treatment and at least three months after the last dose of study drug.&#xD;
&#xD;
          7. Ability to understand and willingness to sign a written informed consent form (the&#xD;
             consent form must be signed by the patient prior to any study-specific procedures).&#xD;
&#xD;
          8. Willingness and ability to comply with study procedures and follow-up examination.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients who meet any of the following exclusion criteria are not to be enrolled in this&#xD;
        study:&#xD;
&#xD;
          1. Patients diagnosed with acute promyelocytic leukemia or t(9;22)(q34.1;q11.2); BCR-ABL1&#xD;
             positive AML patients.&#xD;
&#xD;
          2. The persistent toxicities caused by previous chemotherapy or radiotherapy has not been&#xD;
             restored to lower than grade 2 by CTCAE 5.0 (except for alopecia).&#xD;
&#xD;
          3. Known leukemia infiltration of the central nervous system.&#xD;
&#xD;
          4. Symptomatic active fungal, bacterial and/or viral infections.&#xD;
&#xD;
          5. Prior history of allogeneic hematopoietic stem cell transplantation or adoptive cell&#xD;
             immunotherapy, autologous hematopoietic stem cell transplantation within 12 months.&#xD;
&#xD;
          6. Within 14 days before the first dose of study drug, received chemotherapy (hydroxyurea&#xD;
             is permitted more than 24 hours before the first dose of study drug), radiotherapy,&#xD;
             surgery, immunotherapy, targeted therapy, biological therapy or any investigational&#xD;
             treatment.&#xD;
&#xD;
          7. Within 7 days before the first dose of study drug, received a strong and/or moderate&#xD;
             CYP3A inducer and/or Inhibitor.&#xD;
&#xD;
          8. At the discretion of the investigator, gastrointestinal diseases that affect the&#xD;
             absorption of APG-2575.&#xD;
&#xD;
          9. Any other condition or circumstance, at the discretion of the investigator, that&#xD;
             patients would be unsuitable for participation in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yifan Zhai, M.D., Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Suzhou Yasheng Pharmaceutical Co., Ltd.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jie Jin, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>the First Affiliated Hospital, College of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jie Jin, M.D.</last_name>
    <phone>+86 571-87236896</phone>
    <email>jiej0503@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qiang Jiang, Professor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chongqing University Cancer Hospital</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yi Gong, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guandong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yang Liang, Professor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guangdong Provincial People's Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianyu Wong, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henan Tumor Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xudong Wei, Professor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Union Hospital medical college Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qiubo Li, Professor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhongnan Hospital of Hunan university</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430071</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fuling Zhou, Professor</last_name>
    </contact>
    <contact_backup>
      <last_name>Jianying Zhou, Professor</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Xiangya Hospital Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yajing Xu, Master</last_name>
    </contact>
    <contact_backup>
      <last_name>Qun He, Master</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The First affiliated hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suning Chen, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai The Sixth People' s Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chunkang Chang, Professor</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>West China Hospital of Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610044</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiao Shuai, M.D.</last_name>
      <phone>18980606797</phone>
      <email>5397781@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>the First Affiliated Hospital, College of Medicine, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jie Jin, M.D.</last_name>
      <phone>+86 571-87236896</phone>
      <email>jiej0503@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>August 3, 2020</study_first_submitted>
  <study_first_submitted_qc>August 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2020</study_first_posted>
  <last_update_submitted>March 10, 2023</last_update_submitted>
  <last_update_submitted_qc>March 10, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">March 14, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>APG-2575</keyword>
  <keyword>Acute Myeloid Leukaemia (AML)</keyword>
  <keyword>Bcl-2 Inhibitor</keyword>
  <keyword>Myeloid Malignancy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT04501120
org study id: APG2575AC101
nct id: NCT04501120
lead sponsor: 
collaborator: 
has dmc: No
is fda regulated drug: No
is fda regulated device: No
The purpose of this study is to assess the safety, pharmacokinetic profile of APG-2575 single
      agent and in combination with HHT/AZA in patients with relapsed/refractory AML and related
      myeloid malignancies.
This is an open-label, multi-center Phase Ib study of safety, PK of APG-2575 as single agent
      or in combination with HHT or AZA in relapsed/refractory AML and related myeloid malignancies
      patients.

      This study consists of three stages: The first stage is the APG-2575 single agent
      dose-escalation study. The second stage is the APG-2575 combined with HHT/AZA dose-escalation
      study. The third stage is the MTD/RP2D expansion cohort study of the combination regimen.
allocation: Non-Randomized
intervention model: Parallel Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: Dose Limiting Toxicities (DLT)
time frame: 28 days
description: DLT will be graded according to NCI CTCAE Version 5.0. DLT will be defined as clinically significant drug-related adverse events during cycle one.
measure: Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose(RP2D)
time frame: 28 days
description: MTD/RP2D will be determined based on DLTs observed during cycle one.
measure: Maximum plasma concentration (Cmax)
time frame: 28 days
description: Cmax of APG-2575 will be assessed in the patients in single agent or combo study.
measure: Area under the plasma concentration versus time curve (AUC)
time frame: 28 days
description: AUC of APG-2575 will be assessed in the patients in single agent or combo study.
measure: Objective Response Rate (ORR)
time frame: Up to 6 cycles (each cycle is 28 days).
description: ORR is defined by CR+ CRi + PR(according to IWG AML(2003)).Response will be evaluated on cycle 1 and every even cycles till completing 6 cycles treatment or end of treatment.
measure: progression free survival (PFS)
time frame: Up to 2 years.
description: From date of treatment start until the date of progression or the date of death due to any cause.
measure: duration of response (DOR)
time frame: Up to 2 years.
description: From date of response until the date of progression.
measure: overall survival (OS)
time frame: Up to 2 years.
description: From date of treatment start until the date of death due to any cause.
arm group label: APG2575 single agent
arm group type: Experimental
description: APG-2575 orally once daily starting from 200mg and will be increased in subsequent cohorts to 400mg, 600mg, 800mg, to determine the MTD/RP2D.
arm group label: APG2575+reduced-dose HHT
arm group type: Experimental
description: APG-2575 MTD/RP2D-1 and MTD/RP2D combines with reduced-dose HHT in R/R AML, MPAL, BPDCN, CMML.
arm group label: APG2575+ standard-dose HHT
arm group type: Experimental
description: APG-2575 MTD/RP2D-1 and MTD/RP2D combines with standard-dose HHT in R/R AML, MPAL, BPDCN, CMML.
arm group label: APG2575+ AZA
arm group type: Experimental
description: APG-2575 MTD/RP2D-1 and MTD/RP2D combines with AZA in R/R AML, MPAL, BPDCN, CMML.
arm group label: APG2575+ AZA(HR-MDS.)
arm group type: Experimental
description: APG-2575 MTD/RP2D-1 and MTD/RP2D combines with AZA in HR-MDS.
arm group label: APG2575+ AZA(Naïve AML.)
arm group type: Experimental
description: APG-2575 MTD/RP2D-1 and MTD/RP2D combines with AZA in treatment naïve AML.
intervention type: Drug
intervention name: APG-2575
description: APG-2575 orally once daily, every 28 days as a cycle.
arm group label: APG2575 single agent
arm group label: APG2575+ AZA
arm group label: APG2575+ AZA(Naïve AML.)
arm group label: APG2575+ standard-dose HHT
arm group label: APG2575+reduced-dose HHT
intervention type: Drug
intervention name: Reduced-dose HHT
description: 1mg IV QD on Days 1-14 (28-day cycle).
arm group label: APG2575+reduced-dose HHT
intervention type: Drug
intervention name: standard-dose HHT
description: 2mg/m^2 IV QD on Days 1-7 (28-day cycle).
arm group label: APG2575+ standard-dose HHT
intervention type: Drug
intervention name: Azacitidine
description: 75 mg/m^2 SC or Iv gtt QD on Days 1- 7 (28-day cycle).
arm group label: APG2575+ AZA
arm group label: APG2575+ AZA(HR-MDS.)
arm group label: APG2575+ AZA(Naïve AML.)
intervention type: Drug
intervention name: APG-2575
description: APG-2575 orally once daily for 14 days, every 28 days as a cycle.
arm group label: APG2575+ AZA(HR-MDS.)
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: No
last name: Yifan Zhai, M.D., Ph.D.
role: Study Director
affiliation: Suzhou Yasheng Pharmaceutical Co., Ltd.
last name: Jie Jin, M.D.
role: Principal Investigator
affiliation: the First Affiliated Hospital, College of Medicine
last name: Jie Jin, M.D.
phone: +86 571-87236896
email: jiej0503@163.com
facility: 
status: Recruiting
contact: 
facility: 
status: Not yet recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
contact backup: 
facility: 
status: Recruiting
contact: 
contact backup: 
facility: 
status: Recruiting
contact: 
facility: 
status: Not yet recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
country: China
responsible party type: Sponsor
mesh term: Leukemia, Myeloid
mesh term: Leukemia, Myeloid, Acute
mesh term: Neoplasms
mesh term: Azacitidine